SENSEX    38248.26       300.38    |    NIFTY    11534.9       64.15 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Divi's Labs rises after successful USFDA inspection of Telangana unit
17-May-18   10:04 Hrs IST

The announcement was made after market hours yesterday, 16 May 2018.

Meanwhile, the S&P BSE Sensex was down 35.37 points, or 0.10% to 35,352.51.

On the BSE, 16,000 shares were traded in the counter so far compared with average daily volumes of 30,000 shares in the past two weeks. The stock had hit a high of Rs 1,213 and a low of Rs 1,175.30 so far during the day. The stock hit a 52-week high of Rs 1,220 on 11 May 2018. The stock hit a 52-week low of Rs 533.10 on 29 May 2017.

Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana State had an inspection by the US Food and Drug Administration (USFDA) from 14 to 16 May 2018. This was a general Current Good Manufacturing Practice (cGMP) inspection by the USFDA. The inspection has been concluded with no 483 observations.

As per USFDA, form 483 observations are issued after conclusion of inspection to notify the company's management of objectionable conditions at its facility.

Net profit of Divi's Laboratories declined 16.27% to Rs 224.66 crore on 6.29% rise in net sales to Rs 1037.88 crore in Q3 December 2017 over Q3 December 2016.

Divi's Laboratories is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.89 79.86 1.14
United Kingdom (GBP) 1.12 1.00 89.25 1.27
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.88 0.79 70.16 1.00
Commodities << ALL Commodities
GOLDAHMD293610
SILVERAHMD366600
CRUDEOILMUMBAI4597-80
COPPERMUMBAI405.1-7.45
 Market News << ALL News
   Disclaimer   |   BSE Disclosure  |   Privacy Policy   |   Investor Protection   |   Inactive Account
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INB010982739   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2008 certified)